Giredestrant (GDC-9545, CAS No.: 1953133-47-5), an orally active and selective estrogen receptor antagonist, potently competes with Estradiol for binding and induces a conformational change within the ER ligand binding domain. Synonyms: selective estrogen receptor degrader...
The cheapest research grade volociximab biosimilar (anti-human integrin α5β1 monoclonal antibody, mAb) for ELISA, neutralization, in vivo functional assays such as bioanalytical PK and ADA assays, and those in vitro and in vivo assays for...
The cheapest research grade toralizumab biosimilar (anti-human CD40L/CD154 monoclonal antibody, mAb) for ELISA, neutralization, in vivo functional assays such as bioanalytical PK and ADA assays, and those in vitro and in vivo assays for studying...
The cheapest research grade zalutumumab biosimilar (anti-human EGFR monoclonal antibody, mAb) for ELISA, neutralization, in vivo functional assays such as bioanalytical PK and ADA assays, and those in vitro and in vivo assays for studying...
The cheapest research grade satumomab biosimilar (anti-human TAG-72 monoclonal antibody, mAb) for ELISA, neutralization, in vivo functional assays such as bioanalytical PK and ADA assays, and those in vitro and in vivo assays for studying...
The cheapest research grade ruplizumab biosimilar (anti-human CD40L/CD40/CD154 monoclonal antibody, mAb) for ELISA, neutralization, in vivo functional assays such as bioanalytical PK and ADA assays, and those in vitro and in vivo assays for studying...
The cheapest research grade pateclizumab biosimilar (anti-human lymphotoxin alpha (LT-α) monoclonal antibody, mAb) for ELISA, neutralization, in vivo functional assays such as bioanalytical PK and ADA assays, and those in vitro and in vivo assays...
Conditions of optimal IFN alpha 2a Protein performance should be determined experimentally by the investigator.
TAK-931 (CAS No.: 1330782-76-7), A Selective and ATP-Competitive Cell Division Cycle 7 (CDC7) Kinase Inhibitor. Synonyms: cell division cycle 7 inhibitor TAK-931, Simurosertib, TAK931, CDC7 kinase inhibitor
